ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2019
Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments.
Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03912883 (Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting
Who cites it
24 citing papers in PubMed, 44 citations in OpenAlex.
- High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Evaluation of the Proliferation Marker Ki-67 for Improved Risk Stratification of Prostate Cancer Patients Under Active Surveillance.Diagnostics (Basel, Switzerland) · 2026Article
- Tumour-based epigenetic signatures as markers of prostate cancer aggressiveness after radical prostatectomy.British journal of cancer · 2026Article
- Combined MYC Activation and PTEN Loss Drives Molecular Features of Aggressive Preinvasive Lesions in Mouse Prostate.Molecular cancer research : MCR · 2026Article
- Review
- High Ki-67 labeling index correlates with aggressive clinicopathological features in papillary thyroid carcinoma: a retrospective study.Thyroid research · 2025Article
- Prognostic Significance of Ki67 Expression in Prostate Cancer in Nigerians: A Single-Center Study.Cureus · 2025Article
- Redefining prostate cancer risk stratification: a pioneering strategy to estimate outcome based on Ki67 immunoscoring.Biomarker research · 2024Article
- Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts.World journal of clinical cases · 2024Article
- Prognostic significance of grade of malignancy based on histopathological differentiation and Ki-67 in pancreatic ductal adenocarcinoma.Cancer biology & medicine · 2024Article
- A novel nomogram model based on Ki-67 characteristic expression to predict prognosis in head and neck squamous cell carcinoma.Frontiers in oncology · 2024Article
- Metastatic prostate cancer diagnosed by fine-needle aspiration: Contemporary cytopathologic and biomarker assessment with clinical correlates.Cancer cytopathology · 2023Review
- Differences in the pathogenetic characteristics of prostate cancer in the transitional and peripheral zones and the possible molecular biological mechanisms.Frontiers in oncology · 2023Review
- CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality.Journal of hematology & oncology · 2022Article
- Utility of Serum Ki-67 as a Marker for Malignancy in Dogs.Animals : an open access journal from MDPI · 2022Article
- Article
- High Inter- and Intratumoral Variability of Ki67 Labeling Index in Newly Diagnosed Prostate Cancer with High Gleason Scores.Pathobiology : journal of immunopathology, molecular and cellular biology · 2022Article
- Fascin-1 is associated with recurrence in solitary fibrous tumor/hemangiopericytoma.Molecular and clinical oncology · 2021Article
- Preoperative histogram parameters of dynamic contrast-enhanced MRI as a potential imaging biomarker for assessing the expression of Ki-67 in prostate cancer.Cancer medicine · 2021Article
- [Molecular pathology of urogenital tumors : Recommendations from the 2019 International Society of Urological Pathology (ISUP) Consensus Conference].Der Pathologe · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
Abstract
Standard clinical parameters fail to accurately differentiate indolent from aggressive prostate cancer. Our previous studies showed that immunohistochemical testing for Ki-67 improved prediction of prostate cancer death in a previous cohort of conservatively treated clinically localized prostate cancer. However there is a need for validation of usage with whole biopsy sections rather than tissue micro-arrays for use in routine diagnostics. Prostate cancer biopsy cases were identified in the UK, between 1990 and 2003, treated conservatively. Tumor extent and prostate-specific antigen (PSA) serum measurements were available. Biopsy cases were centrally reviewed by three uropathologists and Gleason conformed to contemporary ISUP 2014 criteria. Follow-up was through cancer registries up until 2012. Deaths were divided into those from prostate cancer and those from other causes. The percentage of Ki-67 in tumor cells was evaluated by immunohistochemistry on whole biopsy sections and was available for 756 patients. This percentage was used in analysis of cancer specific survival using a Cox proportional hazards model. In univariate analysis, the interquartile hazard ratio (HR) (95% confidence intervals) for continuous Ki-67 was 1.68 (1.49, 1.89), χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.